Colorectal Cancer

Disease and Advanced Drug Delivery Strategies

1st Edition - November 19, 2023
Editors: Bhupendra G. Prajapati, Anil K. Philip, Sankha Bhattacharya
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 8 7 0 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 8 6 2 4 - 7
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 8 7 1 - 3

Colorectal Cancer: Disease and Advanced Drug Delivery Strategies examines the combined impact of basic clinical and medical treatments as well as recent advances in the field… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Colorectal Cancer: Disease and Advanced Drug Delivery Strategies examines the combined impact of basic clinical and medical treatments as well as recent advances in the field of colorectal cancer. With a strong focus towards colorectal cancer diagnosis, disease drug delivery, and diagnosis, the book also examines the Tumor microenvironment-responsive and site-specific nanoparticles for cancer theragnostics. Sections provide the opportunity to understand and diagnose the disease, describes screening methods, and update on drugs, including nano- and immunotherapy. Content includes clinical trials in colorectal cancer research and disease models that help better direct researchers and clinicians on how to diagnose and treat colorectal cancer.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
Preface
Acknowledgments
Chapter 1. Colorectal cancer: understanding of disease
Abstract
1.1 Introduction
1.2 Understanding of disease: colorectal cancer
1.3 Diagnosis for colorectal cancer
1.4 Treatment for colorectal cancer
1.5 Recent advances in the therapeutic interventions of colorectal cancer
1.6 Conclusion
Abbreviations
References
Chapter 2. Impact of the microbiome on colorectal cancer development
Abstract
2.1 Introduction
2.2 Gut microbiome and colorectal cancer
2.3 Gut microbiota and its derived metabolites
2.4 Host microbiota interactions with genomes and epigenomes
2.5 Linking antibiotic-microbiome: risk and attribution of leaky gut to colorectal cancer
2.6 Intestinal stem cells and colorectal cancer
2.7 Prognostic or diagnostic microbiome-associated early diagnosis
2.8 Therapeutic impact of the gut microbiome on the efficacy of chemotherapy
2.9 Preventive dietary mediators and their protective potential in colorectal cancer
2.10 Concluding remarks and outlook
Abbreviations
References
Chapter 3. Advanced microfluidic systems for the colorectal cancer diagnosis and its clinical application
Abstract
3.1 Introduction
3.2 Tumor markers used for colorectal cancer detection
3.3 Conventional methods used for diagnosis of colorectal cancer
3.4 Microfluidic system
3.5 Microfluidic models for diagnosis of cancer
3.6 Conclusion
References
Chapter 4. Transarterial radioembolization and its impacts on colon cancer treatment and diagnosis
Abstract
4.1 Introduction
4.2 Colorectal cancer risk assessment
4.3 Colorectal cancer diagnosis and staging procedures
4.4 Treatments
4.5 Transarterial radioembolization
4.6 Principle and concept of radioembolization
4.7 Types of radionuclides microspheres
4.8 Glass microspheres
4.9 Resin microspheres
4.10 Radioembolization with 90Y as primary therapy for liver MCRC (Metastatic Colorectal Cancer)
4.11 Radioembolization with 90Y in grouping with second- or third-line chemotherapy for hepatic MCRC
4.12 Treatment methodology
4.13 Conclusion and future outlook
References
Chapter 5. Current drug therapy for colorectal cancer
Abstract
5.1 Introduction
5.2 Molecular targets of the colorectal cancer drugs
5.3 Targeted drug therapy in colorectal cancer
5.4 Multidrug therapy approaches
5.5 Chances of drug resistance with colorectal targeting drugs
5.6 Conclusion
Acknowledgment
Abbreviation
References
Chapter 6. Recent advancements in immunotherapy for colorectal cancer
Abstract
6.1 Introduction
6.2 Immunotherapy for colorectal cancers
6.3 Immuno-checkpoints for colorectal cancer
6.4 Immune-modulators
6.5 Cell transfer therapies
6.6 Monoclonal antibodies and vaccines
6.7 Recent promising biomarkers for colorectal cancer
6.8 Nanoengineered cancer immunotherapy approaches
6.9 Conclusion and open question
Funding
List of abbreviation
References
Chapter 7. Novel targeting formulations in colorectal cancer
Abstract
7.1 Introduction
7.2 Epidemiology of colorectal cancer
7.3 Pathogenesis of colorectal cancer
7.4 Synthetic antiinflammatory drugs for colorectal cancer
7.5 Cyclodextrin-based nanoparticles
7.6 Conclusions
References
Chapter 8. Polymeric nanoparticles in colorectal cancer
Abstract
8.1 Introduction
8.2 Polymers for drug delivery
8.3 Mechanisms of drug delivery and release in polymeric drug-delivery systems
8.4 Polymer degradation mechanism
8.5 Mechanisms of drug delivery and release in polymeric drug delivery systems
8.6 Therapeutic use of polymeric nanoparticles in colon cancer
8.7 Drugs for colon cancer therapy
8.8 Monoclonal antibodies drugs
8.9 Colon cancer treatments using polymers
8.10 Polymeric nanocarriers sensitive to temperature and redox potential
8.11 Patents and clinical trials
8.12 Conclusion
Acknowledgments
Abbreviations
References
Chapter 9. Lipid nanoparticles in colorectal cancer
Abstract
9.1 Introduction
9.2 Mechanisms of action
9.3 Current lipid-based nanoplatforms
9.4 Deliverable targets for colorectal cancer treatment
9.5 Preclinical and clinical studies
9.6 Clinical studies
9.7 Conclusions
Acknowledgments
Funding
Author contributions
Competing interests
Availability statement
References
Chapter 10. Micro and nanoemulsions in colorectal cancer
Abstract
10.1 Introduction
10.2 Microemulsion
10.3 Nanoemulsion
10.4 Formulation of microemulsion/nanoemulsion
10.5 Components of microemulsion/nanoemulsion
10.6 Overview of patent situation
10.7 Pharmacokinetics and pharmacodynamics of developed nanoemulsion/microemulsion for colorectal cancer
10.8 Regulatory aspects
10.9 Challenges and future prospects
10.10 Conclusion
Abbreviations
References
Chapter 11. A unique compilation of whole-systems approaches to curtail colon cancer through herbal medicine
Abstract
11.1 Introduction
11.2 Herbal medicine in colorectal cancer
11.3 Regulatory status of these medicines
11.4 Clinical trials
11.5 Conclusion
References
Chapter 12. Bacteriotherapy in colorectal cancer
Abstract
12.1 Colorectal cancer
12.2 Bacteriotherapy in treatment of colorectal cancer
12.3 Conclusion
List of abbreviations
References
Chapter 13. Biomarkers and theranostics in colorectal cancer
Abstract
13.1 Introduction
13.2 Biomarkers and theranostics in early diagnosis of colorectal cancer
13.3 Targeted therapies for treating metastatic colorectal cancer: role of biomarkers and theranostics
13.4 Theranostic nanoagents for diagnosis and treatment of colorectal cancer
13.5 Diagnostic biomarkers in colorectal cancer
13.6 Theranostic and biomarkers in colorectal cancer: future perspectives
13.7 Conclusion
References
Chapter 14. Advance precision medicine to combat colorectal cancer
Abstract
14.1 Introduction
14.2 Development of advance precision medicine
14.3 Advanced precision medicine
14.4 Treatment with advance precision medicine
14.5 Challenges and opportunities
14.6 Conclusion
References
Chapter 15. Recent updates of clinical trials for colorectal cancer
Abstract
15.1 Introduction
15.2 Classification of colorectal cancer based on immune score
15.3 Causes and etiogenesis of colorectal cancer
15.4 Prevention of colorectal cancer
15.5 Molecular target of colorectal cancer
15.6 Combining immunotherapy with other treatments for patients with colorectal cancer
15.7 Targeted therapies for metastatic colorectal cancer
15.8 Food and Drug Administration-approved drugs in a clinical trial for colorectal cancer
15.9 Identification of categorical risk in screening
15.10 Therapeutic vaccine for colorectal cancer
15.11 Natural anticancer and combination agents for colorectal cancer
15.12 Advancement in clinical trials for the treatment of colorectal cancer
15.13 History and future challenges of clinical trials of colorectal cancer
15.14 Conclusion
Abbreviations
References
Chapter 16. Disease models in colorectal cancer research
Abstract
16.1 Introduction
16.2 Search strategy
16.3 In vitro colorectal cancer models
16.4 Animal models for colorectal cancer
16.5 Chemically-triggered colorectal cancer
16.6 Mutagen-induced germline mutation models
16.7 Genetically engineered models
16.8 Other animal models
16.9 Conclusion
Funding
Conflict of interests
References
Chapter 17. An outlook into liposomal drug delivery of chemotherapeutic agents to combat colorectal cancer
Abstract
17.1 Introduction
17.2 Pros and cons of liposomes for colorectal chemotherapy
17.3 Liposomal approaches for colorectal chemotherapy
17.4 Triggering modalities of liposomal formulations
17.5 Future perspective
17.6 Conclusion
Abbreviations
References
Chapter 18. Novel targeting strategies on signaling pathways of colorectal cancer
Abstract
18.1 Introduction
18.2 Molecular pathways involved in colorectal cancer
18.3 Colorectal cancer-related signaling pathways
18.4 Novel targeting strategy for targeting signaling pathway responsible for colorectal cancer
18.5 Conclusion
Abbreviations
References
Chapter 19. Decipher the role of cancer stem cells in colorectal cancer based on molecular pathology and its clinical significance
Abstract
19.1 Introduction
19.2 Normal stem cells—elixir of life and cancer stem cells—the enemy within
19.3 Molecular pathology of cancer stem cells
19.4 Insight into the clinical implication of cancer stem cells
19.5 Targeted drug delivery system in targeting colorectal cancer stem cells
19.6 Future perspective and challenges ahead for cancer stem cell-based therapy
19.7 Conclusion
References
Index

Bhupendra G. Prajapati

Bhupendra G. Prajapati is Professor in the Department of Pharmaceutics at Shree S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. An alumnus of Hemchandracharya North Gujarat University (Doctorate) and M.S. University of Baroda (B.Pharm and M.Pharm), he has over 22 years of experience in academia, research, and industry. Dr. Prajapati has received numerous accolades, including the AICTE's Career Award for Young Teacher and the President Award for Staff Excellence in Research and Capacity Building from Ganpat University. With over 80 national and international publications, he has secured various research grants and holds multiple patents in NDDS. He has supervised numerous Ph.D. and PG research scholars and delivered over 50 expert talks globally. As an editor of 10 international books and contributor of 70 book chapters, his research focuses on lipid-based drug delivery and nanotech formulations. Dr. Prajapati is an active member of IPA, APTI, and CRSIC.

Affiliations and expertise

Professor, Department of Pharmaceutics and Pharmaceutical Technology, Shree S.K. Patel College of Pharmaceutical Education & Research, Faculty of Pharmacy, Ganpat University, India

Anil K. Philip

Dr. Anil Philip is currently working as Associate Dean (Head), School of Pharmacy, University of Nizwa, Oman. Among other credentials, he served as a member of the Health and Social Sciences sectorial grant committee of The Research Council, Oman, and as Faculty Mentored Undergraduate Research Program general supervisor to promote undergraduate research at the University of Nizwa. His research objectives and achievements have been in controlling/modifying the release of small/large molecules targeted to GI space using phase-transited delivery systems. He has worked extensively in the field of controlled/ modified drug release systems. Currently, his research focuses on developing nano-drug delivery systems, which can be targeted to the various body organs. He has guided students in areas of targeted drug delivery, has more than 40 original research publications in international peer-reviewed journals, and two patents on drug delivery systems.

Affiliations and expertise

Associate Dean (Head), School of Pharmacy, University of Nizwa, Oman

Sankha Bhattacharya

Dr. Sankha Bhattacharya did his Post Doctorate from the Indian Institute of Technology (BHU), Varanasi, INDIA (August 2018-August 2019) in cancer nanomedicine and molecular pharmaceutics. He is currently serving as an Associate Professor in the Department of Pharmaceutics, School of Pharmacy & Technology Management Shirpur, SVKM'S NMIMS Deemed-to-be University, India with 9.3 years of Research and Teaching experiences. He has published more than 32 national and 18 international papers in high impact factor and peer-reviewed journals. He also published five book chapters on the global platform.

Affiliations and expertise

Associate Professor, Department of Pharmaceutics, School of Pharmacy and Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Colorectal Cancer

Disease and Advanced Drug Delivery Strategies

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Bhupendra G. Prajapati

Anil K. Philip

Sankha Bhattacharya